Submit to Pharmaceutics Review for Pharmaceutics Edit a Special Issue

Journal Menu

Journal Browser

Special Issue "Application of Photodynamic Therapy in Dermatology"

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2711

Share This Special Issue

Special Issue Editors

Prof. Dr. Joanna Bartosińska

E-Mail Website
Guest Editor

1. Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, 20-081 Lublin, Poland
2. Department of Cosmetology and Aesthetic Dermatology, Medical University of Lublin, 20-081 Lublin, Poland
Interests: psoriasis; chronic urticaria; photodynamic therapy; actinic keratosis; skin cancers; cosmetics
Special Issues, Collections and Topics in MDPI journals

Dr. Dorota Kowalczuk

E-Mail Website
Guest Editor

Department of Medicinal Chemistry, Faculty of Pharmacy, Medical University of Lublin, Lublin, Poland
Interests: photodynamic therapy; photosensitizers; combination therapies; drug delivery systems; photodiagnosis; immunomodulation; dosimetry; fluorescence; skin diseases; malignancy

Special Issue Information

Dear Colleagues,

Owing to its relatively non-invasive nature, good tolerability, low systemic toxicity, and ability to produce a desirable cosmetic outcome, photodynamic therapy (PDT) has been employed in many medical applications. It has been proven to be an effective therapeutic tool in the treatment of various skin conditions, such as actinic keratosis/cheilitis, NMSC, photoaging, acne, rosacea, sebaceous hyperplasia, and verrucae, to name just a few. PDT is also used in the diagnosis of various types of cancer, as well as in the treatment of some infectious and autoimmune diseases.

In PDT, in order to induce photochemical and photobiological reactions that are destined to destroy the targeted, pathologically changed cells, a combination of three elements, i.e., a photosensitizer, oxygen, and light, is required. The most popular types of topical photosensitizer prodrugs used in PDT are 5-aminolevulinic acid (5-ALA) and its derivatives.

Although the PDT method is being continuously improved, it still has limitations and awaits perfecting. Thus, in order to devise new ways to enhance its efficacy, produce more efficient photosensitizers and new light sources, further scientific studies are necessary.

Therefore, we would be delighted to receive research articles, reviews, communications and case studies that shed more light onto any new approaches to improve the efficacy of PDT, as well as papers pertaining to PDT-associated immunotherapy, new radiation systems and new light-delivering devices.

Prof. Dr. Joanna Bartosińska
Dr. Dorota Kowalczuk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

photodynamic therapy
photosensitizers
combination therapies
drug delivery systems
photodiagnosis
immunomodulation
dosimetry
fluorescence
skin diseases
malignancy

Published Papers (3 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle

Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial

Carmen Salinas-Gilabert

Francisco Gómez García

and

Pharmaceutics 2023, 15(1), 30; https://doi.org/10.3390/pharmaceutics15010030 - 22 Dec 2022

Viewed by 735

Abstract

Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 photodynamic therapy applied once a week for four sessions, with orabase cream; group 2 low-power laser application with orabase cream; and group 3 inactive laser with triamcinolone acetonide 0.1%. Patient pain was evaluated, and the Thongprasom severity score, the Oral Health Impact Profile-14 (OHIP-14), and the Hamilton anxiety and depression scale at one and three months of follow-up. (ClinicalTrials.gov Identifier: NCT05127083). Results: Pain decreased significantly over time in all groups, though the symptoms relapsed over follow-up at one and three months in group 3. The OHIP-14 score improved significantly in groups 1 and 2 (p < 0.05), and this improvement was maintained after three months. Lesion resolution evaluated by the Thongprasom score at one month showed significant differences between groups 1 and 3 (p = 0.032) and between groups 2 and 3 (p = 0.024). Conclusions: Photodynamic therapy and photobiomodulation once a week for four weeks are safe and non-invasive treatment options, with the important advantage of lacking adverse effects. Further studies are needed to confirm it. Full article

(This article belongs to the Special Issue Application of Photodynamic Therapy in Dermatology)

► Show Figures

Figure 1

Open AccessArticle

Effects of Temoporfin-Based Photodynamic Therapy on the In Vitro Antibacterial Activity and Biocompatibility of Gelatin-Hyaluronic Acid Cross-Linked Hydrogel Membranes

and

Pharmaceutics 2022, 14(11), 2314; https://doi.org/10.3390/pharmaceutics14112314 - 27 Oct 2022

Cited by 1 | Viewed by 875

Abstract

This study was performed to design a hydrogel membrane that exhibits antibacterial properties and guides different tissues. Gelatin and hyaluronic acid were used as the main structures, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) was used as a cross-linker, and temoporfin was used as an antibacterial agent. The results revealed that the hydrogel membrane impregnated with temoporfin (HM-T) had a fixation index of >89%. Temoporfin was used in conjunction with a diode laser and did not significantly affect EDC-induced cross-linking. The inhibitory activity of temoporfin showed that HM-T15 and HM-T30 (light exposure for 15 and 30 min, respectively) had remarkable antibacterial properties. The cell survival rate of HM-T15 was 73% of that of the control group, indicating that temoporfin exposure for 15 min did not exert cytotoxic effects on L-929 cells. HM and HM-T15 hydrogel membranes showed good cell adhesion and proliferation after 14 days of dark incubation. However, the hydrogel membrane containing temoporfin significantly reduced pro-inflammatory gene expression. In summary, the HM-T15 group showed potential as a biodegradable material for biocompatible tissue-guarded regeneration membranes with antibacterial properties. This study demonstrated the potential of temoporfin for innovative biomaterials and delivery systems applied to new regenerative periodontal therapies. Full article

(This article belongs to the Special Issue Application of Photodynamic Therapy in Dermatology)

► Show Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview

Photodynamic Therapy as an Effective Treatment for Cutaneous Lymphomas

and

Pharmaceutics 2023, 15(1), 47; https://doi.org/10.3390/pharmaceutics15010047 - 23 Dec 2022

Cited by 1 | Viewed by 753

Abstract

Topical photodynamic therapy (PDT) is a non-invasive treatment modality frequently used in dermatology to treat superficial skin cancers but also some inflammatory or infectious dermatoses. PDT appears a more and more promising therapeutic option also for cutaneous lymphomas, either of T- or B-cell origin. It is a well-tolerated treatment and has excellent cosmetic outcomes, less side effects compared to other therapies (steroids, surgery, radiotherapy, and so on), no particular contraindications, and is easily repeatable in case of relapses. However, how PDT works in the treatment of cutaneous lymphoproliferative diseases is poorly understood and the literature data are still controversial. Further randomized, controlled clinical trials involving a greater number of patients and centers with a long follow-up are necessary to assess the efficacy of PDT and establish a unique standardized treatment protocol in relation to the lymphomatous disease and the type, thickness, and location of the lesions. Full article

(This article belongs to the Special Issue Application of Photodynamic Therapy in Dermatology)

► Show Figures

Journal Menu

Journal Browser

Special Issue "Application of Photodynamic Therapy in Dermatology"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (3 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI